Fig. 2 | Scientific Reports

Fig. 2

From: Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy

Fig. 2

Distribution of causative pathogens in 115 patients with breakthrough bloodstream infection during tigecycline therapy. This figure includes polymicrobial bloodstream infections in which each microorganism was counted. *Others include Bacteroides fragilis (2 cases), Enterococcus faecium (2), Klebsiella oxytoca (2), Stenotrophomonas maltophilia (2), Serratia marcescens (2), Actinomyces species (1), Alcaligenes faecalis (1), Burkholderia cepacian (1), Chryseobacterium indologenes (1), Citrobacter amalonaticus (1), Enterobacter aerogenes (1), Enterobacter asburiae (1), Enterococcus faecalis (1), Klebsiella aerogenes (1), Moraxella osloensis (1) and Morganella morganii (1).

Back to article page